ArticleMedicine2026
The role of mitochondrial fusion protein 2 in regulating ER stress in premature placental aging: A case-control study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Advanced maternal age (AMA) is associated with an increased risk of adverse perinatal outcomes, which may be attributed to premature placental aging. Previous studies have demonstrated that mitochondrial fusion protein 2 (Mfn2) plays a critical role in aging-related neurodegenerative disorders, metabolic diseases, and vascular pathologies. However, its expression in AMA pregnancies and its impact on placental function remain poorly understood. This study aimed to investigate the expression patterns of Mfn2 in placental tissues from AMA pregnancies and elucidate its regulatory role in endoplasmic reticulum (ER) stress through the protein kinase R-like ER kinase (PERK) signaling pathway. The downregulation of Mfn2 expression in AMA exacerbates placental senescence by dysregulating ER stress via PERK. Mfn2 binds to PERK, inhibits phosphorylation, and alleviates oxidative stress and senescence, highlighting its therapeutic potential. Placental tissues from 20 women with AMA and 20 young women were analyzed using real-time quantitative reverse transcription PCR. An H2O2-induced HTR-8/SVneo trophoblast cell line senescence model was established. Functional assays (cell counting kit-8, wound healing, Transwell, and β-galactosidase staining) and oxidative stress markers (reactive oxygen species/malondialdehyde/superoxide dismutase) were evaluated. Western blotting was used to assess the expression of PERK pathway proteins (phosphorylated protein kinase R-like endoplasmic reticulum kinase, activating transcription factor 4, and CCAAT/enhancer binding protein homologous protein) and senescence markers (P16 and P53). Immunoprecipitation verified the Mfn2-PERK interaction. Mfn2 expression was significantly downregulated in AMA placentas and negatively correlated with PERK expression. Mfn2 overexpression reversed the H2O2-induced suppression of trophoblast viability, migration, invasion, and senescence while reducing the levels of reactive oxygen species and malondialdehyde and restoring the activity of superoxide dismutase. Mfn2 inhibited PERK pathway activation (phosphorylated protein kinase R-like endoplasmic reticulum kinase, activating transcription factor 4, and CCAAT/enhancer binding protein homologous protein) and the expression of senescence markers (P16/P53). Mfn2 interacted directly with PERK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.